Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Academic Article uri icon

Overview

abstract

  • OBJECTIVE: To compare the survival impact of diagnosing recurrent disease by routine surveillance testing versus clinical symptomatology in patients with recurrent epithelial ovarian cancer (EOC) who have achieved a complete response following primary therapy. METHODS: We identified all patients who underwent primary surgery for EOC at two institutions between 1/1997 and 12/2004 and were diagnosed with recurrent disease following a complete clinical response to primary chemotherapy. Survival and post-recurrence management were compared between asymptomatic patients in which recurrent disease was diagnosed at a scheduled visit by routine surveillance testing and symptomatic patients in which recurrent disease was diagnosed based on clinical symptomatology at an unscheduled office visit or hospitalization. RESULTS: Of the 121 patients that met inclusion criteria, 22 (18.2%) were diagnosed with a symptomatic recurrence. Median primary PFS was similar for asymptomatic and symptomatic patients (24.8 versus 22.6 months, P = 0.36); however, post-recurrence survival was significantly greater in asymptomatic patients (45.0 versus 29.4 months, P = 0.006). Secondary cytoreductive surgery (SCRS) was attempted equally in both groups (41% versus 32%, P = NS); however, optimal residual disease (

publication date

  • February 12, 2010

Research

keywords

  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms

Identity

Scopus Document Identifier

  • 77950187418

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2010.01.014

PubMed ID

  • 20153027

Additional Document Info

volume

  • 117

issue

  • 2